Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

NCT04028063 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Soft Tissue Sarcoma
Advanced Soft Tissue Sarcoma

Interventions

DRUG: Balstilimab
DRUG: Zalifrelimab
DRUG: Doxorubicin
DRUG: Botensilimab

Sponsor

University of Colorado, Denver

Collaborators

[object Object]